This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyerhardt, J. A. Articles by Fuchs, C. S. Search for Related Content PubMed PubMed Citation Articles by Meyerhardt, J. A. Articles by Fuchs, C. S. Related Articles Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803

Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S. Fuchs

From the Dana-Farber Cancer Institute, Boston, MA; Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic Foundation, Rochester MN; Hôpital du Sacré-Coeur de Montréal, Quebec, Canada; Stritch School of Medicine, Loyola University, Maywood, IL; and Ohio State University, Columbus, OH

Corresponding author: Jeffrey A. Meyerhardt, MD, MPH, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: jmeyerhardt{at}partners.org

Purpose Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied.

Patients and Methods We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death.

Results In this cohort of patients with stage III cancer, 35% of patients were overweight (BMI, 25 to 29.9 kg/m²), and 34% were obese (BMI 30 kg/m²). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m²), the multivariate hazard ratio for disease-free survival was 1.00 (95% CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m²) and 1.24 (95% CI, 0.84 to 1.83) for those with class II to III obesity (BMI 35 kg/m²) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality.

Conclusion Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.

Supported by Grants No. CA32291; CA33601; CA77651; CA25224; CO15; CA38926, CA32101, CA46282; CA21076; P50CA127003; R01 CA 118553-01A2; and K07CA097992 from the National Cancer Institute. Also supported by Pharmacia & Upjohn Co, now Pfizer Oncology.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer
  Jennifer K. Litton, Ana M. Gonzalez-Angulo, Carla L. Warneke, Aman U. Buzdar, Shu-Wan Kau, Melissa Bondy, Somdat Mahabir, Gabriel N. Hortobagyi, and Abenaa M. Brewster
  JCO 2008 26: 4072-4077 [Abstract] [Full Text]
• Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis
  Chad J. Creighton, Angelo Casa, ZaWaunyka Lazard, Shixia Huang, Anna Tsimelzon, Susan G. Hilsenbeck, Charles Kent Osborne, and Adrian V. Lee
  JCO 2008 26: 4078-4085 [Abstract] [Full Text]

Related Editorial

• Obesity and Cancer Treatment: Weighing the Evidence
  Jennifer J. Griggs and Michael S. Sabel
  JCO 2008 26: 4060-4062 [Full Text]

Related Correspondence

• Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes: Need for Prospective and Comprehensive Data
  Kathryn M. Field, Matthew Croxford, Ian Hastie, Frank Chen, Suzanne Kosmider, Jayesh Desai, and Peter Gibbs
  JCO 2009 27: 1524-1526 [Full Text]

This article has been cited by other articles:

				K. M. Field, M. Croxford, I. Hastie, F. Chen, S. Kosmider, J. Desai, and P. Gibbs Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes: Need for Prospective and Comprehensive Data J. Clin. Oncol., March 20, 2009; 27(9): 1524 - 1526. [Full Text] [PDF]

				S. S. Sridhar and P. J. Goodwin Insulin-Insulin-Like Growth Factor Axis and Colon Cancer J. Clin. Oncol., January 10, 2009; 27(2): 165 - 167. [Full Text] [PDF]

				J. J. Griggs and M. S. Sabel Obesity and Cancer Treatment: Weighing the Evidence J. Clin. Oncol., September 1, 2008; 26(25): 4060 - 4062. [Full Text] [PDF]